Abstract:Non-small cell lung cancer (NSCLC) is one of the most deadly cancers worldwide, with poor prognosis once the disease has progressed past the point at which surgery is a viable option. Whilst chemotherapy has improved survival over recent decades, there is still great need for improvements in treatments for patients with advanced disease. Over the last decade, a variety of such drugs have received market approval for treating NSCLC, with a variety of others in the pipeline. Here, we review the development of targeted therapies for the treatment of advanced or metastatic NSCLC, including those already in clinical practice and those in early trials. The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. Moreover, the discovery of EGFR mutations and ALK rearrangements has enabled the identification of patients who are more likely to benefit from a specific drug. The recent approval of the immune checkpoint inhibitor nivolumab, along with the designation of alectinib and MPDL3280A as breakthrough therapies by the FDA, demonstrates how rapidly this area of research is expanding. Over the last decade there has been significant progress made in the treatment of advanced NSCLC, and the large and varied selection of drugs currently undergoing trials provide great promise for improving the prognosis of this highly prevalent and deadly form of cancer.

Progress of Diagnosis and Treatment of Lung Cancer in 2010

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

New progress in immunotherapy of lung cancer

Medical Treatment of Advanced Non-Small Cell Lung Cancer: Progress in 2014

Important clinical research progress in lung cancer in 2022

Lung Cancer Management in 2010.

Advances in the management of elderly patients with advanced non-small cell lung cancer

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

[Treatment of Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer after Resistance to Crizotinib].

Treatment of Elderly Patients or Patients Who Are Performance Status 2 (PS2) with Advanced Non-Small Cell Lung Cancer Without Epidermal Growth Factor Receptor ( EGFR ) Mutations and Anaplastic Lymphoma Kinase ( ALK ) Translocations – Still a Daily Challenge

Advancements in radiotherapy for lung cancer in China

Advances in Clinical Cancer Therapy in 2009

Scientific Advances in Lung Cancer 2015

New Approaches for Individual Treatment of Advanced Non-Small Cell Lung Cancer

Research progress on drug resistance mechanism and management of targeted therapy for ALK-positive non-small cell lung cancer

Clinical evaluation of therapeutic methods on advanced stage lung cancer in shanghai area inrecent ten years

Progress of EGFR-TKI and ALK/ROS1 Inhibitors in Advanced Non-Small Cell Lung Cancer.

The latest research progress of ALK/ROS1 inhibitors in the treatment of advanced non-small cell lung cancer

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives

Recent advances and remaining challenges in lung cancer therapy

Advances in Clinical Trials of Targeted Therapy and Immunotherapy of Lung Cancer in 2018